Froimson Mark 4

What Happened

• Mark Froimson, a director of Pacira BioSciences, sold 500 shares of PCRX on March 17, 2026. The reported price was $21.81 per share, for a total transaction value of $10,905. This was a sale (code S) reported on the Form 4; sales by directors are often routine portfolio activity and do not by themselves indicate a change in company outlook.

Key Details

• Transaction date and price: 2026-03-17 — 500 shares at $21.81 each.
• Total proceeds: $10,905.
• Shares owned after transaction: Not specified in the provided filing excerpt (see the full Form 4 for post-transaction holdings).
• Footnotes / plan disclosure: No 10b5‑1 plan, tax-withholding, or other special footnotes were provided in the summary data here.
• Filing timeliness: Form filed on 2026-03-19 for a 2026-03-17 transaction — appears to have been filed within the usual two-business-day window.

Context

• This was a straight sale of shares (S). Sales by insiders can be for many personal reasons and are not the same signal as purchases, which are often viewed as more bullish. For full details (post-transaction holdings, any footnotes, or plan disclosures), review the complete Form 4 filing (Accession: 0001628280-26-019890).